PRAVASTATIN SODIUM (pravastatin sodium) by Biocon is hmg-coa reductase, the rate-limiting enzyme that converts hmg-coa to mevalonate, a precursor of cholesterol. Approved for clinically evident chd. First approved in 2018.
Drug data last refreshed 20h ago
HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.
Pravastatin Sodium 80 mg Tablets Under Fasting Conditions
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions
Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions
Pravastatin Sodium 40 mg Tablets Food Challenge Study
Worked on PRAVASTATIN SODIUM at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.